Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $2.20 at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price reduced by equities researchers at UBS Group from $5.00 to $2.20 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s target price suggests a potential downside of 6.18% from the company’s current price.

Several other equities research analysts also recently weighed in on ZNTL. Guggenheim cut their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Finally, Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.69.

Zentalis Pharmaceuticals Trading Down 2.3 %

NASDAQ:ZNTL opened at $2.35 on Tuesday. The stock has a market capitalization of $167.10 million, a PE ratio of -0.95 and a beta of 1.86. The firm has a fifty day simple moving average of $3.04 and a 200 day simple moving average of $3.32. Zentalis Pharmaceuticals has a 1-year low of $2.13 and a 1-year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Barclays PLC increased its holdings in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the last quarter. GSA Capital Partners LLP lifted its position in Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Verition Fund Management LLC increased its position in Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after buying an additional 951,500 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after buying an additional 399,745 shares during the period. Finally, Primecap Management Co. CA lifted its position in shares of Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after buying an additional 265,690 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.